Covalent Biologics
Undisclosed
Pre-clinicalActive
Key Facts
About Constructive Bio
Constructive Bio is pioneering a dual-technology platform combining whole-genome synthesis and engineered translation to reprogram the genetic code of microorganisms. This enables the scalable, fermentation-based production of peptide and protein therapeutics containing precisely placed non-canonical amino acids, unlocking new chemistries and functions. The company is positioned to create next-generation drug candidates, such as stabilized GLP-1 analogs and site-specific antibody-drug conjugates, with potential advantages in stability, efficacy, and target engagement. Its foundational science is based on peer-reviewed research from Professor Jason Chin's lab.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |